107 related articles for article (PubMed ID: 2493230)
1. Analysis of amikacin-resistant Pseudomonas aeruginosa developing in patients receiving amikacin.
Maloney J; Rimland D; Stephens DS; Terry P; Whitney AM
Arch Intern Med; 1989 Mar; 149(3):630-4. PubMed ID: 2493230
[TBL] [Abstract][Full Text] [Related]
2. Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa.
Islam S; Jalal S; Wretlind B
Clin Microbiol Infect; 2004 Oct; 10(10):877-83. PubMed ID: 15373880
[TBL] [Abstract][Full Text] [Related]
3. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
[TBL] [Abstract][Full Text] [Related]
4. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.
Lerner SA; Quinn JP
Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
[TBL] [Abstract][Full Text] [Related]
6. Changes in the rates of antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa between 2002 and 2004 in a tertiary-care teaching hospital in Turkey.
Işeri L; Bayraktar MR
New Microbiol; 2008 Jul; 31(3):351-5. PubMed ID: 18843889
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa.
Tam VH; Chang KT; LaRocco MT; Schilling AN; McCauley SK; Poole K; Garey KW
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):309-14. PubMed ID: 17617302
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility profile of Pseudomonas aeruginosa isolates in Egypt.
Gad GF; el-Domany RA; Ashour HM
J Urol; 2008 Jul; 180(1):176-81. PubMed ID: 18499192
[TBL] [Abstract][Full Text] [Related]
9. [Bacteriological monitoring of the treatment of Pseudomonas aeruginosa infections with amikacin administrated at once-daily dosis in patients with cystic fibrosis].
Canis F; Husson MO; Vic P; Ategbo S; Turck D; Courcol R; Leclerc H
Pathol Biol (Paris); 1995 Apr; 43(4):343-51. PubMed ID: 7567127
[TBL] [Abstract][Full Text] [Related]
10. Beta-lactam resistant Pseudomonas aeruginosa strains emerging during therapy: synergistic resistance mechanisms.
Pagani L; Debiaggi M; Tenni R; Cereda PM; Landini P; Romero E
Microbiologica; 1988 Jan; 11(1):47-53. PubMed ID: 2832709
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic sensitivity and plasmid profiles of Pseudomonas aeruginosa.
Igumbor E; Gwanzura L; Chirara M; Obi C; Muza D
Cent Afr J Med; 2000 Nov; 46(11):296-300. PubMed ID: 12002119
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital.
Wolter DJ; Smith-Moland E; Goering RV; Hanson ND; Lister PD
Diagn Microbiol Infect Dis; 2004 Sep; 50(1):43-50. PubMed ID: 15380277
[TBL] [Abstract][Full Text] [Related]
13. Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres).
Dubois V; Arpin C; Dupart V; Scavelli A; Coulange L; André C; Fischer I; Grobost F; Brochet JP; Lagrange I; Dutilh B; Jullin J; Noury P; Larribet G; Quentin C
J Antimicrob Chemother; 2008 Aug; 62(2):316-23. PubMed ID: 18467306
[TBL] [Abstract][Full Text] [Related]
14. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.
Wolter DJ; Black JA; Lister PD; Hanson ND
J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resistance mechanisms.
Gad GF; El-Domany RA; Zaki S; Ashour HM
J Antimicrob Chemother; 2007 Nov; 60(5):1010-7. PubMed ID: 17906321
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa isolates from different medical institutions.
Nitzan Y; Sharon R; Maayan M; Steuerman C
Isr J Med Sci; 1985 Oct; 21(10):798-803. PubMed ID: 3935600
[TBL] [Abstract][Full Text] [Related]
18. Occurrence and mechanisms of amikacin resistance and its association with beta-lactamases in Pseudomonas aeruginosa: a Korean nationwide study.
Kim JY; Park YJ; Kwon HJ; Han K; Kang MW; Woo GJ
J Antimicrob Chemother; 2008 Sep; 62(3):479-83. PubMed ID: 18606785
[TBL] [Abstract][Full Text] [Related]
19. Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity.
Pournaras S; Maniati M; Spanakis N; Ikonomidis A; Tassios PT; Tsakris A; Legakis NJ; Maniatis AN
J Antimicrob Chemother; 2005 Oct; 56(4):761-4. PubMed ID: 16115825
[TBL] [Abstract][Full Text] [Related]
20. Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan.
Hsueh PR; Tseng SP; Teng LJ; Ho SW
Clin Microbiol Infect; 2005 Aug; 11(8):670-3. PubMed ID: 16008621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
